£810 / $1295 / €985
We have recently revised downwards our 2012 pharmaceutical sales growth for Peru, due to the recent price cuts in the prescription drug sector, which accounts for over 74% of total pharmaceutical sales. Still, our projected compound annual growth rate (CAGR) between 2011 and 2016 remains largely unchanged as BMI believes Peru still offers considerable longer-term benefits to local and foreign pharmaceutical companies because of the country's ageing population, increasing disease burden and the expected change in drug consumption patterns.
Headline Expenditure Projections
Pharmaceuticals: PEN3.90bn (US$1.42bn) in 2011 to PEN4.11bn (US$1.57bn) in 2012; +5.3% in local currency terms and +10.4% in US dollar terms. Forecast revised downwards from Q4 12 due to price cuts in the prescription drug sector.
Healthcare: PEN19.52bn (US$7.09bn) in 2011 to PEN20.73bn (US$7.90bn) in 2012; +6.2% in local currency terms and +11.4% in US dollar terms. US dollar forecast unchanged from Q4 12.
Medical devices: PEN897mn (US$326mn) in 2011 to PEN954mn (US$363mn) in 2012; +6.3% in local currency terms and +11.6% in US dollar terms. Forecast slightly lower than Q4 12 on account of macroeconomic factors.
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.